KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
Presenter: Peter Schmid, UK; Discussant: Giuseppe Curigliano, Italy;
ESMO Virtual Plenary Resources
Monthly presentations of the latest, original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. Slides and webcasts from ESMO Virtual Plenaries are open to all, ESMO Members and free ESMO Account holders, according to the presenters' agreement to release them.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Sponsors
IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer
Presenter: Jens Huober, Switzerland; Discussant: Evandro de Azambuja, Belgium;
IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab
Presenter: Stephen Liu, USA; Discussant: Anne-Marie Dingemans, the Netherlands;
Randomised Phase III Trial Data on the Efficacy and Safety of Cemiplimab as Opposed to Chemotherapy in Patients with Progressive Advanced Cervical Cancer
Presenter: Krishnansu S. Tewari, USA; Discussant: Mansoor Mirza, Denmark;
Randomised Phase II Trial Data on the Combination of 2nd-line Osimertinib and Bevacizumab Versus Standard of Care Osimertinib in EGFR T790M-mutated Advanced NSCLC
Presenter: Ross Soo, Singapore; Discussant: Edward Garon, USA;
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Presenter: Solange Peters, Switzerland; Discussant Federico Cappuzzo, Italy;
Efficacy of Everolimus in Patients With HR+/HER2- High Risk Early Stage Breast Cancer
Presenter: Thomas Bachelot, France; Discussant Peter Schmid, UK;